Malignant Colorectal Neoplasm — Research

Malignant Colorectal Neoplasm — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-13	169,282	`("Malignant Colorectal Neoplasm"[tiab] OR "Colorectal Cancer"[tiab] OR "Malignant Colorectal Tumor"[tiab])`	2026-09-13	pubmed
Last 5 years	2021-01-01 → 2026-12-31	65,243	`("Malignant Colorectal Neoplasm"[tiab] OR "Colorectal Cancer"[tiab] OR "Malignant Colorectal Tumor"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-13	pubmed
Last 12 months	2025-09-13 → 2026-09-13	14,135	`("Malignant Colorectal Neoplasm"[tiab] OR "Colorectal Cancer"[tiab] OR "Malignant Colorectal Tumor"[tiab]) AND (2025/09/13:2026/09/13[dp])`	2026-09-13	pubmed

Data updated 19 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (357)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 201–225 of 357 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.
· Cancer Discov · 2017 · PMID 28363909 · validated civic_curation pubmed
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
· Cancer Discov · 2018 · PMID 29431699 · validated civic_curation pubmed
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
· J Clin Oncol · 2010 · PMID 20008640 · validated civic_curation pubmed
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.